The Official Journal of the Turkish Society Of Clinical Microbiology and Infectious Diseases (KLİMİK)


Filter Newest Oldest Showing 1-20 of 60 results
Review Article / VOLUME 5, ISSUE 3, SEPTEMBER 2023

COVID-19: An Update on Epidemiology, Prevention and Treatment, September-2023

Serap Şimşek-Yavuz

After the World Health Organization (WHO) declared an end to COVID-19 as a global public health emergency on May 5, 2023, we have entered a new era in the pandemic, and most countries have already returned to normal life. This declaration was resulted from the 12-month downward trend of the pandemic, increased immunity due to the highly effective vaccines, decreased death rates, and decreased pressure on once overwhelmed (...) Read More

Original Article / VOLUME 5, ISSUE 3, SEPTEMBER 2023

Long-Term Symptoms and Quality of Life in Persons with COVID-19

Nuriye Yalçın-Çolak and others

COVID-19, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is a zoonotic infection that emerged in Wuhan province of China in December 2019. SARS-COV-2 is a Betacoronavirus that is classified in Riboviria realm, Nidovirales order, and Coronaviridae family (1). Although the fatality rate of SARS-CoV-2 (2.6%) is lower than SARS-CoV (11%) and MERS-CoV (35-50%), it was much more severe worldwide (...) Read More

Brief Report / VOLUME 5, ISSUE 3, SEPTEMBER 2023

B Cell Subtypes in Individuals Received mRNA or Inactivated Vaccine Boosters After Fully Vaccinated with CoronaVac: A Longitudinal Study

Zeynep Ece Kuloğlu and others

In the COVID-19 pandemic, it is essential to estimate the immune responses to various COVID-19 vaccinations to estimate the efficacy of the vaccines. During the ongoing pandemic, different vaccine types and vaccination strategies affect the cellular and molecular elements of innate and adaptive immune systems. Therefore, testing the effectiveness of COVID-19 vaccines in different vaccination (...) Read More

Original Article / VOLUME 5, ISSUE 2, JUNE 2023

Clinical Evaluation of Commercial HARDSON COVID-19 Antigen Rapid Test Kit for Routine COVID-19 Diagnosis

Reza Kamali Kakhki* and others

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a respiratory disease agent belonging to the Betacoronavirus genera. The genome of the virus translates into four major structural proteins, including spike (S), nucleocapsid (N), membrane (M), and envelop (E) proteins. During the pandemic, huge numbers of mutations (...) Read More

Original Article / VOLUME 5, ISSUE 2, JUNE 2023

The Impact of Vaccination Among Hospitalized Patients with the Diagnosis of COVID-19

Yeşim Yıldız and others

Vaccines to prevent SARS-CoV-2 infection are the most promising and effective approach to curb the COVID-19 pandemic, as well as to reduce hospitalizations and prevent mortality.  In our country, the CoronaVac (Sinovac Biotech, China) vaccine started to be administered as of January 13, 2021, and the Comirnaty (BNT162b2, Pfizer-BioNTech) vaccine as (...) Read More

Original Article / VOLUME 5, ISSUE 2, JUNE 2023

COVID-19 Among Patients with Psoriasis: A Single-Center Retrospective Cross-Sectional Study

Özge Kaya and others

Psoriasis, a chronic inflammatory disease, has a multifactorial etiology, including genetic, environmental, and behavioral factors. Since psoriasis is an immune system-mediated disease, immunosuppressive agents and biological treatments are frequently used in its treatment; however, these agents are known to increase the risk of infection. This situation (...) Read More

Original Article / VOLUME 5, ISSUE 1, MARCH 2023

Evaluation of Inflammation-Based Prognostic Risk Scores in Predicting in-Hospital Mortality Risk in COVID-19 Patients: A Cross-Sectional Retrospective Study

Çaşıt Olgun Çelik and others

An acute respiratory syndrome (COVID-19), caused by a novel coronavirus (SARS-CoV-2), has spread from China worldwide and caused a pandemic that brought severe medical, social, and economic problems. The COVID-19 infection results in various clinical presentations ranging from an asymptomatic (...) Read More

Original Article / VOLUME 4, ISSUE 4, DECEMBER 2022

Thyroid Dysfunction among the Patients with Critical COVID-19

Hande Özportakal and others

The world has been fighting against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for more than two years, leading to more than 605 million cases and 6.4 million deaths as of September 11, 2022. Since the angiotensin-converting enzyme (ACE) is the functional receptor for SARS-CoV-2, predominantly expressed by the alveoli (...) Read More

Original Article / VOLUME 4, ISSUE 4, DECEMBER 2022

Analysis of the Prophylactic use of Hydroxychloroquine at the Beginning of the COVID-19 Pandemic Among Physicians

Mehmet Gökhan Gönenli and others

Healthcare workers were on the front line of the global effort against COVID-19. Thousands of physicians died from COVID-19 in many countries. In addition, difficulties in accessing personal protective equipment (PPE), lack of training, and workforce shortages have exposed the vulnerability of healthcare workers who desperately sought other options to protect (...) Read More

Original Article / VOLUME 4, ISSUE 4, DECEMBER 2022

Comparison of CURB-65 Pneumonia Severity Score, Quick COVID-19 Severity Index, and Brescia-COVID Respiratory Severity Scale in Emergently Hospitalized COVID-19 Patients with Pneumonia

İbrahim Toker and others

Coronavirus disease 2019 (COVID-19) occurred with different levels of severity, and different criteria for hospitalizations were suggested, considering risk factors for poor outcomes, such as advanced age, comorbidities, lymphopenia, and high C-reactive protein (CRP) levels. The most severe complication of COVID-19 is viral pneumonia, which is often manifested by diffuse bilateral lung (...) Read More

Original Article / VOLUME 4, ISSUE 3, SEPTEMBER 2022

Maternal Stress and Neonatal Nutrition during the COVID-19 Era

Alara Altıntaş and others

COVID-19 has been the main focus of the world since the beginning of 2020. The virus has infected over 180 million people and caused about 6 million deaths worldwide up to February of 2022. With its rapid spread, the new coronavirus posed enormous economic, environmental, and social challenges together with health threats to the entire (...) Read More

Original Article / VOLUME 4, ISSUE 3, SEPTEMBER 2022

The Effect of the Pandemic on Antifungal Use: What Has Changed?

Vildan Avkan-Oğuz and others

Before coronavirus disease 2019 (COVID-19), antimicrobial stewardship (AMS) programs were essential for managing multidrug-resistant Gram-negative bacterial infections. In contrast, antifungal stewardship (AFS) programs were uncommon as a component of AMS. During the COVID-19 pandemic, both AMS and AFS programs have lost (...) Read More

Original Article / VOLUME 4, ISSUE 3, SEPTEMBER 2022

Antibiotic Use among Patients Hospitalized with COVID-19 and Treated in Three Different Clinics

Oğuz Evlice and others

The clinical spectrum of COVID-19 varies, ranging from asymptomatic infection to critical illness. The most commonly used tool for the classification of disease severity is the National Institute of Health (NIH) severity scale, which has four categories: mild, moderate, severe, and critical. Patients with moderate and severe clinical courses are followed up in wards, while those with (...) Read More